Monotherapy with labetalol for hypertensive patients with normal and impaired renal function

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Hypertension is a prevalent cardiovascular condition requiring effective management.
• Labetalol is an alpha- and beta-adrenergic blocker used for blood pressure control.
• Understanding labetalol's efficacy and safety profile in diverse hypertensive populations is crucial.

Purpose of the Study:

• To evaluate the efficacy and safety of labetalol in patients with essential and renal hypertension.
• To determine the onset of hypotensive response following oral labetalol administration.
• To assess potential adverse effects, including exercise/postural hypotension and impact on renal function.

Main Methods:

• A study involving 41 hypertensive patients receiving divided daily doses of labetalol (150-2,400 mg) for 1-64 months.
• Assessment of monotherapy adequacy in patients with essential and renal hypertension.
• Monitoring of blood pressure response after a single 200 mg oral dose.
• Evaluation for exercise-induced or postural hypotension and changes in overall renal function.

Main Results:

• Labetalol monotherapy was adequate for 12/19 patients with essential hypertension and 15/22 with renal hypertension.
• A hypotensive response was observed 1.5 to 2 hours after a single 200 mg oral dose.
• No exercise or postural hypotension was noted at the doses administered.
• No reduction in overall renal function was attributed to labetalol treatment.

Conclusions:

• Labetalol is an effective antihypertensive agent for both essential and renal hypertension.
• The drug provides a predictable hypotensive response and is well-tolerated regarding postural and exercise effects.
• Labetalol does not appear to compromise overall renal function in hypertensive patients.